Selonterra: Funding, Investors & Team (Sep 2026)
Selonterra, Inc. is a San Francisco Bay Area venture capital funded Delaware corporation. Selonterra fundamentally transforms therapeutic approaches to neurodegenerative disorders, including Alzheimer’s disease, by a rigorous exploitation of our novel insights into the genetic causes of disease. Selonterra discovered that the altered DNA of genetic variants associated with neurodegenerative disorders, including Alzheimer’s disease and Parkinson’s disease, affect transcription factor binding sites and thereby change the expression of genes nearby. In our Alzheimer’s disease program we develop small molecules that modulate the function of an unexploited, druggable target and will fundamentally change Alzheimer’s disease therapy. We complement our highly relevant extensive experience in start-ups with a global network of specialized collaborator companies and thereby apply state-of-the art technologies to execute our program in a capital efficient way.
Selonterra has raised $5.0M across 2 funding rounds on record, the most recent an undisclosed round of $2.5M announced in Oct 2024.
That round is below the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Selonterra Company Profile and Key Stats
Latest funding round on record: Oct 2024.
Selonterra Funding Rounds
Selonterra raised $2.5M in an undisclosed round announced in Mar 2023.
1.6 years later, an undisclosed round of $2.5M was announced in Oct 2024.
Selonterra Founders and Leadership Team
No contact details are on record for this team yet.
Selonterra Funding Compared to Other Biotechnology Startups
Selonterra's latest round of $2.5M is below the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Selonterra in Biotechnology and San Mateo
Companies Similar to Selonterra
Noveome Biotherapeutics, Inc. is an advanced biopharmaceutical company that focuses on groundbreaking…
XiltriX North America is an information technology company that specializes in monitoring, predictive…
Novir is an emerging diagnostic biotechnology company with an unmatched team of professionals and trusted…
Abcuro’s mission is to develop a new class of immune-modulatory bio-therapeutics for treating both…
Georgiamune Inc. is a privately-owned biotechnology company that specializes in advanced immunotherapy…
Bridge to Life was founded with the mission of improving organ transplants by licensing and developing new…
InduPro is a biotechnology firm that focuses on protein therapeutics and technologies related to cell-surface…
Paterna BioSciences, Inc. is a pioneering biotechnology company dedicated to solving the significant…
Legendary Bio's solidarity is a determined spotlight on introducing another period of quality guideline.
Cataract surgery is the single most common procedure performed in the United States annually. Despite…
InSitu Biologics is a developer of a drug delivery platform designed to focus on development of new and…
Remedium Bio is a gene therapy company in the Boston area that is dedicated to developing cures for severe…
Selonterra Funding FAQs
What does Selonterra do?
Selonterra, Inc. is a San Francisco Bay Area venture capital funded Delaware corporation. Selonterra fundamentally transforms therapeutic approaches to neurodegenerative disorders, including Alzheimer’s disease, by a rigorous exploitation of our novel insights into the genetic causes of disease. Selonterra discovered that the altered DNA of genetic variants associated with neurodegenerative disorders, including Alzheimer’s disease and Parkinson’s disease, affect transcription factor binding sites and thereby change the expression of genes nearby. In our Alzheimer’s disease program we develop small molecules that modulate the function of an unexploited, druggable target and will fundamentally change Alzheimer’s disease therapy. We complement our highly relevant extensive experience in start-ups with a global network of specialized collaborator companies and thereby apply state-of-the art technologies to execute our program in a capital efficient way.
How much funding has Selonterra raised?
Selonterra has raised $5.0M across 2 rounds on record. The most recent is an undisclosed round of $2.5M announced in Oct 2024.
When did Selonterra last raise funding?
Selonterra's most recent funding round on record is an undisclosed round of $2.5M, announced in Oct 2024.
Who founded Selonterra?
FundedIQ lists Anne Urfer Buchwalder (Founder) at Selonterra.
Who is the CEO of Selonterra?
Roman Urfer is listed as CEO at Selonterra.
Where is Selonterra headquartered?
Selonterra is based in San Mateo, California, United States.
How many employees does Selonterra have?
Selonterra is in the 1-10 employee band.
How does Selonterra's funding compare to other Biotechnology startups?
Selonterra's latest round of $2.5M is below the $8.0M median round size for Biotechnology companies on FundedIQ across 4,179 tracked companies over the last two years.
About FundedIQ's Selonterra Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Selonterra is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.